PRLD
Prelude Therapeutics Inc

1,143
Mkt Cap
$102.47M
Volume
223,337.00
52W High
$4.22
52W Low
$0.6101
PE Ratio
-1.12
PRLD Fundamentals
Price
$1.89
Prev Close
$1.81
Open
$1.83
50D MA
$1.91
Beta
1.74
Avg. Volume
477,421.59
EPS (Annual)
-$1.68
P/B
1.75
Rev/Employee
$53,435.11
Loading...
Loading...
News
all
press releases
Prelude Therapeutics (NASDAQ:PRLD) Rating Lowered to Hold at Wall Street Zen
Wall Street Zen cut Prelude Therapeutics from a "buy" rating to a "hold" rating in a research note on Sunday...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Up 28.5% in December
Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest...
MarketBeat·21d ago
News Placeholder
Prelude Therapeutics (NASDAQ:PRLD) Stock Price Up 2.1% - What's Next?
Prelude Therapeutics (NASDAQ:PRLD) Trading 2.1% Higher - Time to Buy...
MarketBeat·27d ago
News Placeholder
Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus
GS stands out as Zacks showcases how its stock picks like MU and PRLD delivered strong gains despite a shaky market.
Zacks·2mo ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...
PR Newswire·2mo ago
News Placeholder
Prelude Therapeutics (NASDAQ:PRLD) Issues Earnings Results
Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.26) earnings per share for the quarter, topping the consensus...
MarketBeat·2mo ago
News Placeholder
Prelude Therapeutics Inc Q3 Loss Decreases, Beats Estimates
(RTTNews) - Prelude Therapeutics Inc (PRLD) revealed Loss for third quarter that decreased from the same period last year and beat the Street estimates...
Nasdaq News: Markets·2mo ago
News Placeholder
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prelude Therapeutics Incorporated (Prelude or the Company...
Business Wire·2mo ago
<
...
1
>

Latest PRLD News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.